Radiopharmaceutical Therapy

Radium 223 was approved in May 2013 as a survival agent and is marketed in the U.S. under the name Xofigo. The drug is used to shrink metastatic bone tumors in men suffering from advanced forms of the disease, and has the potential to benefit as many as 60,000 men annually. Recent research has shown that Xofigo-administered via 6 monthly injections-reduced the risk of death from prostate cancer by 30 percent. In addition, Xofigo also has a series of quality-of-life benefits, with more time free of the debilitating complications of advanced prostate cancer (bone fractures, spinal cord compression) and reducing pain and suffering for many men with bone tumors.